Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E. coli Nissle 1917 for grass pollen allergic rhinoconjunctivitis
2008-006335-12Phase 2Completed
- Sponsor
- Prof. Dr. med. Margitta Worm
- Start
- Oct 2008
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of escherichia coli nissle 1917 in allergic rhinoconjunctivitis (ARC) and grass pollen allergy (2 arms), sponsored by Prof. Dr. med. Margitta Worm. Primary endpoint: Symptom-medication score. Started Oct 2008; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
allergic rhinoconjunctivitis (ARC)grass pollen allergy
Beyond the preview
Go deeper on 2008-006335-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006335-12.